Xenon Total Current Assets from 2010 to 2024
| XENE Stock | USD 43.15 0.70 1.65% |
Total Current Assets | First Reported 2012-09-30 | Previous Quarter 728.1 M | Current Value 659.6 M | Quarterly Volatility 240.7 M |
Check Xenon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xenon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 6.7 M or Selling General Administrative of 48.9 M, as well as many indicators such as Price To Sales Ratio of 239, Dividend Yield of 0.0 or PTB Ratio of 3.18. Xenon financial statements analysis is a perfect complement when working with Xenon Pharmaceuticals Valuation or Volatility modules.
Xenon | Total Current Assets |
Latest Xenon Pharmaceuticals' Total Current Assets Growth Pattern
Below is the plot of the Total Current Assets of Xenon Pharmaceuticals over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Xenon Pharmaceuticals' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xenon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Current Assets | 10 Years Trend |
|
Total Current Assets |
| Timeline |
Xenon Total Current Assets Regression Statistics
| Arithmetic Mean | 227,857,207 | |
| Geometric Mean | 133,880,555 | |
| Coefficient Of Variation | 109.29 | |
| Mean Deviation | 209,341,503 | |
| Median | 84,942,000 | |
| Standard Deviation | 249,030,769 | |
| Sample Variance | 62016.3T | |
| Range | 632.4M | |
| R-Value | 0.84 | |
| Mean Square Error | 19857.1T | |
| R-Squared | 0.70 | |
| Significance | 0.000095 | |
| Slope | 46,678,456 | |
| Total Sum of Squares | 868228.5T |
Xenon Total Current Assets History
About Xenon Pharmaceuticals Financial Statements
Xenon Pharmaceuticals stakeholders use historical fundamental indicators, such as Xenon Pharmaceuticals' Total Current Assets, to determine how well the company is positioned to perform in the future. Although Xenon Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Xenon Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Xenon Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Xenon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Assets | 645 M | 677.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:Check out the analysis of Xenon Pharmaceuticals Correlation against competitors. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.81) | Quarterly Revenue Growth (1.00) | Return On Assets (0.19) | Return On Equity (0.27) |
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.